로딩 중…
지수 로딩 중…
Voronoi, Inc.
310210· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩194,900-3.75%
2026-06-19
Price Chart
Voronoi, Inc.+105.81%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 3.59T KRW |
| Revenue | 7.51B KRW |
| Net Income | -50.60B KRW |
| Total Assets | 158.75B KRW |
| Net Assets | 91.85B KRW |
| Employees | 147 |
| Value | |
| P/B | 39.05x |
| P/S | 477.43x |
| FCF Yield | -2.06% |
| Profitability | |
| ROE | -55.09% |
| ROA | -31.87% |
| Op. Margin | -824.00% |
| Financial Health | |
| Debt Ratio | 172.84% |
| Total Debt | 32.70B KRW |
| FCF | -73.74B KRW |
| Cash | 13.53B KRW |
| Current Ratio | 11.19x |
| Performance | |
| 1Y Return | 105.81% |
| 1M Return | -19.46% |
| From 52W High | -48.10% |
| 1Y MDD | -50.21% |
| Trading | |
| Volume | 109,797 shares |
| Foreign Own. | 6.58% |
| Per Share | |
| EPS | -2,751 KRW |
| BPS | 5,046 KRW |
Company Info
Established in 2015 in Songdo, Incheon, VORONOI is a new drug development venture company with its own medicinal chemistry research institute. It specializes in developing targeted anticancer drugs for conditions like lung and breast cancer, with VRN11 currently undergoing global clinical phase 1 trials after approvals in Korea, Taiwan, and Hong Kong. The company utilizes its Voronomix platform to accelerate drug development from target selection to candidate substance in 1-1.5 years, demonstrating competitiveness through five technology transfer achievements since 2020. VORONOI is headquartered in Yeonsu-gu, Incheon Metropolitan City.